An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.
Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR.
Steeg PS, et al. Among authors: eccles sa.
Clin Cancer Res. 2009 Jul 15;15:4529. doi: 10.1158/1078-0432.CCR-09-1363.
Clin Cancer Res. 2009.
PMID: 25278743
Free PMC article.
No abstract available.